Haisco Pharmaceutical Group announced that its subsidiary Shanghai Haisco Shennuo Pharmaceutical Technology Co., Ltd. recently received the "Acceptance Notice" from the National Medical Products Administration, involving two new indications for the Innovative Drug HSK0.0445 million tablets: psoriasis and atopic dermatitis. Currently, HSK0.0445 million tablets have obtained clinical trial notices for "interstitial lung disease" and "Behcet's disease," and are undergoing Phase I clinical research. HSK0.0445 million tablets are independently developed small molecule drugs by the company, possessing independent intellectual property rights, with clear targets, definite efficacy, and good safety, providing broad prospects for clinical application.